10.36k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Johnson & Johnson
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Vir Biotechnology, Inc.
Inovio Pharmaceuticals, Inc.
Stock futures were little changed Tuesday evening, struggling for direction after equities sputtered into the close earlier in the day.
What happened Inovio Pharmaceuticals (NASDAQ: INO) stock skyrocketed 82.7% in June, according to data from S&P Global Market Intelligence. The S&P 500 returned 2% last month. In July, shares of the coronavirus vaccine developer, however, have given back a chunk of last month's gain: Through Tuesday, July 7, they're down nearly 11%, while the broader market has returned just over 3%.
The two sides are apparently arguing over several issues, including protocols and information sharing.
GlaxoSmithKline (NYSE: GSK) announced Tuesday that Medicago -- a private company owned by Mitsubishi Tanabe Pharma (OTC: MTZXF) and Philip Morris International (NYSE: PM) -- will use GlaxoSmithKline's adjuvant in a COVID-19 vaccine it expects to enter phase 1 trials this month. Medicago's recombinant coronavirus "Virus-Like Particles" will be combined with Glaxo's pandemic adjuvant system to boost immune response, potentially allowing for less antigen per dose and thus, more available vaccine doses.
In the latest trading session, Johnson & Johnson (JNJ) closed at $142.85, marking a -0.09% move from the previous day.
Pfizer (PFE) closed the most recent trading day at $34.03, moving -1.39% from the previous trading session.
Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.
Efforts to find treatments for the COVID-19 pandemic have taken top priority at many companies in the space, and today, Novavax (NASDAQ: NVAX) and Regeneron Pharmaceuticals (NASDAQ: REGN) got good news from the federal government. Novavax shares were up more than 30% Tuesday morning as investors reacted positively to the latest news from the biotech. As a major player in the race to find a coronavirus vaccine, Novavax got a shot in the arm from the Department of Health and Human Services.
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
The funds will support the rapid development and mass production of the biotech's coronavirus vaccine candidate, NVX-CoV2373.
As a result, investors have begun panic-buying biotech companies on the frontiers of creating new treatments and vaccines for COVID-19. In another article, I discussed how the company made some glaring statements regarding the effectiveness of its antibodies on Fox News. Here, we will focus on what Sorrento is doing in other significant areas to fight the pandemic.
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
Companies in The News Are: BRK.B, D, UBER, REGN, SINA.
A "black swan" event is a highly unusual, utterly unpredictable happening that throws everybody for a loop. As far as the stock market is concerned, black swans are almost always bad. For instance, 9/11 was a black swan.
Novavax lands a massive $1.6 billion award from the federal government's Operation Warp Speed program.
Moderna (NASDAQ: MRNA) was one of the first companies to kick off a phase 1 clinical trial for its investigational COVID-19 vaccine, mRNA-1273. The trial tested the vaccine's safety, immunogenicity (ability to cause immune system response), and reactogenicity (possible side effects). After getting the green light from the U.S. Food and Drug Administration (FDA), Moderna started a phase 2 trial for mRNA-1273 in May. This trial will test the safety, immunogenicity, and reactogenicity of the vaccine in a pool of 600 healthy participants.
The agreement, the first by the Trump administration to support a therapy, comes under the government's "Operation Warp Speed" program that is aimed at faster distribution of vaccines and treatments to fight the new coronavirus when trials are successful. Earlier in the day, Novavax Inc <NVAX.O> received a $1.6 billion grant, the biggest award yet from Operation Warp Speed, to cover testing, manufacturing and sale of a potential coronavirus vaccine. Under the contract with Regeneron, signed with the HHS' Biomedical Advanced Research and Development Authority and the Department of Defense, the doses manufactured under the project will be owned by the federal government.
The federal government is supporting Moderna’s vaccine project with nearly half a billion dollars and has chosen it as one of the first to enter large-scale human trials. The sources said those tensions, which have not been previously reported, have contributed to a delay of more than two weeks in launching the trial of the Moderna’s vaccine candidate, now expected in late July.
The stock market rally had a down day, but not hot EV plays Tesla and Nio. Facebook is in focus late after Mark Zuckerberg met with ad boycott organizers.
SAN FRANCISCO, July 07, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.